Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer

• DOI: 10.1007/s13277-013-0769-0
• Publication Date: 2013-04-05T07:44:31Z
• Authors: Xin-yan Wang; Hai-jiao Wang; Xiu-qin Li
• Keywords: Peroxiredoxin

We investigated the association between peroxiredoxin III (PRX III) and chemotherapy resistance in ovarian cancer. Patient's specimens were taken at time of surgery. Determination is based on whether first diagnosis relapse occurred within 6 months after cessation chemotherapy. PRX expression was immunohistochemically determined paraffin-embedded from platinum-resistant (Pt-resistant) platinum-sensitive (Pt-sensitive) patients. The Pt-resistant group had significantly higher protein compared to Pt-sensitive group. two groups showed no significant differences pathological classification age, although they differed tissue differentiation stage. serous carcinomas, moderately poorly differentiated, stage IV cancer tissues may be associated with drug